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In vivo1 and in vitro2 animal studies have shown that 
local anaesthetics produce dose-related depression of 
cardiac output or negative inotropic action with min- 
imal changes in peripheral vascular resistance. 
Although the electrophysiological basis of local 
anaesthetic action is block of sodium channels, the 
mechanisms of myocardial depression may involve 
additional actions indirectly related to the regulation 
of intracellular calcium such as Ca2 entry into the 
cell or Ca2 release from the sarcoplasmic reticulum. 
Mepivacaine, an amide local anaesthetic agent with 
potency similar to lidocaine, has been reported to 
show clinical effects similar to lidocaine, although 
it is closely related in chemical structure to bupiva- 
caine. Although the negative inotropic effect of 
mepivacaine has been reported in an in vivo study,1 
direct myocardial depression has not yet been 
defined. Therefore, the purpose of this study was to 
determine the degree and mechanisms of direct 
myocardial depression produced by mepivacaine. 
Methods and results 
EXPERIMENT WITH NORMAL K TYRODE’S SOLUTION 
According to a procedure approved by the Yonsei 
University College of Medicine Animal Research 
Committee, the right ventricular papillary muscle 
was removed from female guinea pigs (300–400 g) or 
Sprague–Dawley rats (300–400 g) after intraperi- 
toneal pentobarbital sodium injection (50 mg kg1). 
The tendinous end of the muscle was attached by a 
strut to a GRASS FT03 force transducer. The bath 
was superfused at 37C at a rate of 8 ml min1 with 
normal Tyrode's solution (mmol litre1: Na 143, K 5, 
Ca 2, Cl 127, MgSO4 1.2, HCO3 25, glucose 11, 
Ethylenediaminetetraacetic acid (EDTA) 0.1) 
bubbled with 95% oxygen/5% carbon dioxide 
maintaining mean pH (SD) at 7.4 (0.5). The muscles 
were field-stimulated by a GRASS S44 stimulator 
(GRASS Instruments, Quincy, MA, U.S.A.). 
Membrane potential and its rate of rise during the 
action potential (dV/dt max) was monitored by a 
conventional 3 M KCl-filled glass microelectrode 
(10–20 M) attached to a WPIVF-1 preamplifier. In 
rat experiments, the contractile response to 100 mol 
litre1 mepivacaine in normal Tyrode’s solution only 
was observed. As rat papillary muscle showed 
progressive deterioration of contractility over time, 
time control experiments were performed separately 
to those of mepivacaine administration. 
Whereas mepivacaine 20 mol litre1 caused 
contractile depression at 1–3 Hz stimulation rates, 
mepivacaine 50 and 100 mol litre1 showed depres- 
sion at all stimulation rates. Effects of 50 mol litre1 
were greater than those of 20 mol litre1, and effects of 
100 mol litre1 were greater than those of mepivacaine 
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50 mol litre1 from 0.5 to 3 Hz stimulation rates. 
Contractile depression at 2–3 Hz was greater than 
that at rested state (RS)–0.1 Hz with mepivacaine 
100 mol litre1 (fig. 1A). 
With mepivacaine 20 mol litre1, the contraction 
of guinea pig papillary muscles responded normally 
to field stimulation at all stimulation rates. While 
mepivacaine 50 mol litre1 showed a normal con- 
tractile response at low stimulation rates (RS–1 Hz), 
stimulation block was frequently observed at higher 
stimulation rates (2, 3 Hz). Block of stimulation was 
frequently observed at all stimulation ranges except 
RS with mepivacaine 100 mol litre1. Drug washout 
for 15 min resulted in satisfactory stimulation result- 
ing from the control voltages at all stimulation rates. 
In rat papillary muscles, mepivacaine 100 mol litre1 
produced contractile depression (about 20%) at RS. 
In normal action potential (AP) experiments, 
mepivacaine 100 mol litre1 produced shortening of 
APD50 and APD90 (0.5 Hz: about 18%, 1 Hz: about 
12%, 2 Hz: about 7%) from 0.5 to 2 Hz stimulation 
rates. Mepivacaine 100 mol litre1 significantly 
depressed dV/dt max from 0.5 to 3 Hz, and 
rate-dependent depression of dV/dt max was shown 
at 2 and 3 Hz stimulation rates. There was no ten- 
dency for the muscles to depolarize. 
EXPERIMENTS WITH 26 MMOL LITRE1 K TYRODE’S 
SOLUTION 
Muscle force and APs were also studied in 26 mmol  
litre1 K Tyrode’s solution (mmol litre1: Na 122, 
K 26, Cl 121, Ca 2, MgSO4 1.2, HCO3 25, glucose 
11, EDTA 0.1) with isoprenaline 0.1 mol litre1. A 
sequential increase in stimulation rates from rest to 
1 Hz was performed. Increasing concentrations of 
mepivacaine (50 and 100 mol litre1) were applied 
sequentially in contraction studies, and mepivacaine 
100 mol litre1 was only used to assess the drug 
effect in slow APs. 
Early force development was depressed by about 
30% and 45% with mepivacaine 50 and 100 mol 
litre1, respectively (fig. 1B). In the late developing 
force, mepivacaine 50 and 100 mol litre1 caused an 
approximate 25% and 50% depression, respectively 
(fig. 1C). Stimulation block was not observed. 
Mepivacaine 100 mol litre1 caused neither change 
in resting membrane potential, slow AP amplitude, 
and dV/dt max, nor shortening in AP duration at 0.1, 
0.25, 0.5, and 1 Hz stimulation rates. 
RAPID COOLING CONTRACTURE EXPERIMENTS 
After the 15-min rest at 37C, rapid cooling was 
induced by perfusion at a flow rate of about 50 ml min1 
with 0C normal Tyrode’s solution (5C achieved 
within 1.5 s) in which 95% oxygen/5% carbon dioxide 
was bubbled. Following the measurement of RS rapid 
cooling contracture, the chamber was changed to nor- 
mal Tyrode’s solution at 37C. After full rewarming to 
37 C, stimulation at 0.1 Hz, followed by 1 and 2 Hz 
stimulation rates, was sequentially applied until maxi- 
mal and stable contractions were elicited after 2 Hz. 
Rapid cooling was induced again. Following control 
measurements, muscles were exposed to mepivacaine 
100 mol litre1 for 15 min at 37 C before eliciting the 
rapid cooling contracture. 
After 15-min rest, there was no change in RS rapid 
cooling contracture with mepivacaine 100 mol 
litre1. Peak force at 2 Hz contraction was diminished 
to about 58% of control by mepivacaine 100 mol 
litre1, while contracture was depressed from 5.11 to 
3.86 mN mm2 (about 70% of control). Time to peak 
contracture remained unchanged (control: 13.6 s, 
100 mol litre1 14.5 s). 
In force studies, mean cross-sectional areas were 
0.81 (0.29) (mean (SD), n40) and 0.88 (0.45) mm2 
(mean (SD), n13) in guinea pigs and rats, respectively. 
Repeated measures of analysis of variance 
(ANOVA) followed by Fisher PLSD multiple range 
 
Figure 1 (A) Effects of increasing concentrations of mepivacaine on peak force (PF) in normal K Tyrode’s solution at 
various stimulation rates in guinea pig papillary muscles. Results are plotted as mean (SEM) percentage of control 
(n7). *, †, and ‡ indicate differences (P0.05) from control, mepivacaine 20 mol litre1, and 50 mol litre1, 
respectively (ANOVA). (B) Effects of mepivacaine 50 and 100 mol litre1 on the maximum rate of early force 
development (dFE /dt max) (n5) in 26 mmol litre1 K Tyrode’s solution with isoprenaline 0.1 mol litre1 at various 
stimulation rates in guinea pig papillary muscles, (C) Effects of mepivacaine 50 and 100 mol litre1 on the maximum 
rate of late-force development (dFL /dt max) (n5) in 26 mol litre1 K Tyrode’s solution with isoprenaline 0.1 mol  
litre1 at RS–1 Hz stimulation rates in guinea pig papillary muscle. Results are plotted as mean (SEM) percentage of 
control. *, † Indicate differences (P0.05) from control and mepivacaine 50 mol litre1, respectively (ANOVA). 
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test was applied to test for significant differences in 
the stimulation rates and among the mepivacaine 
concentrations. A P value 0.05 was considered 
significant. 
Comment 
Moderate depression by mepivacaine of cardiac out- 
put and stroke volume (about 15%) with little change 
in systemic vascular resistance has been reported in 
an in vivo animal study. Although etidocaine and 
bupivacaine caused more marked depression of car- 
diac output (about 50% and 100%, respectively), 
lidocaine showed modest depression at the same 
dose.1 In the present study, mepivacaine 50 mol 
litre1 caused an approximate 40% depression of peak 
force, which was comparable to that of lidocaine 
40 mol litre1 in a previous guinea pig papillary 
muscle study.2 
Our results in normal Tyrode’s solution demon- 
strated that depression of myocardial contractility and 
frequency-dependent block of dV/dt max are more 
pronounced at higher (2, 3 Hz) stimulation rates with 
mepivacaine 100 mol litre1. The block of Na 
currents at higher frequencies may account in part for 
the more decreased contractile depression observed 
in guinea pig ventricular muscle at 2 and 3 Hz. 
The present results of force development in 26 
mmol litre1 K Tyrode’s solution suggest the inhi- 
bition of the two different Ca2 release sites on the 
sarcoplasmic reticulum membrane activated by 
depolarization which results from the inhibition of 
Ca2 efflux from the sarcoplasmic reticulum and/or 
depression of Ca2 entry.3 Depression of Ca2 entry 
may contribute to decreased Ca2 content in the sar- 
coplasmic reticulum and may have subsequently 
caused the depression of late developing force. Based 
on the modest depression of Ca2 influx by mepiva- 
caine, the present biphasic contractile depression 
may be caused mainly by inhibition of Ca2 release 
from the sarcoplasmic reticulum. In rat papillary 
muscles, an approximate 20% depression of RS 
contraction by mepivacaine 100 mol litre1 when 
compared with control also provides further support- 
ing evidence for inhibition of Ca2 release from the 
sarcoplasmic reticulum. 
Cerebral symptoms suggesting systemic intoxica- 
tion during caudal analgesia have been reported to 
be associated with a mean mepivacaine concentra- 
tion in blood of 6.27 g ml1 (25.48 mol litre1).4 If 
we assume that the protein binding of mepivacaine at 
this concentration is approximately 40%,5 the free 
plasma concentration will be estimated as 3.76 g ml1 
(15.28 mol litre1). As the therapeutic concentra- 
tions of mepivacaine observed after a lumbar 
extradural administration range from 4 to 6 g ml1 
(5.69–8.54 mol litre1 if we assume 65% protein 
binding at this range of concentration),6 this free 
drug concentration is unlikely to cause myocardial 
depression. However, in the case of inadvertent 
administration of mepivacaine, the transient increase 
in blood concentration may produce cardiac contrac- 
tile depression if we consider peak blood concentra- 
tion of lidocaine to be about 30 g ml1 (128 mol 
litre1) when 3 mg kg1 was injected i.v.7 
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